|Day Low/High||0.09 / 0.11|
|52 Wk Low/High||0.21 / 0.60|
Conference call scheduled for September 21, 2016 at 8:00am ET
Sickle Cell Disease Coalition launches a call to action on neglected disease
Investors in Mast Therapeutics, Inc saw new options become available today, for the April 2017 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 242 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Grant will support evaluation of vepoloxamer as an adjuvant agent to thrombolytic therapy for the treatment of acute stroke
Study conducted with support from a grant awarded by the National Heart, Lung, and Blood Institute, part of the National Institutes of Health
- Ex vivo study results indicate that by limiting unregulated calcium entry, vepoloxamer improves calcium cycling and left ventricle (LV) function in dogs with severe heart failure
- AIR001 significantly lowered pulmonary artery pressures
Very few people expect Mast's compound to become the first, new drug for sickle cell disease in almost 20 years. That's why Mast carries a miniscule $60 million market value.
Study to be conducted with support from a grant awarded by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH)
-Ex vivo study results indicate that by limiting unregulated calcium entry, vepoloxamer improves calcium cycling and left ventricle (LV) function in dogs with severe heart failure
Company anticipates top-line data in Q2 2016
Study met its primary endpoint; AIR001 was generally well-tolerated, with no treatment-related serious adverse events
- Enrollment in largest-ever interventional Phase 3 trial in sickle cell disease has surpassed 90%; top-line data anticipated Q2 2016
- Repeat administration of vepoloxamer in animals with severe heart failure elicited progressively sustained improvement in left ventricle systolic function evident for at least 6 weeks